HK1131340A1 - Compositions comprising alpha-ketoglutarate and their use for modulating muscle performance - Google Patents

Compositions comprising alpha-ketoglutarate and their use for modulating muscle performance

Info

Publication number
HK1131340A1
HK1131340A1 HK09109821.7A HK09109821A HK1131340A1 HK 1131340 A1 HK1131340 A1 HK 1131340A1 HK 09109821 A HK09109821 A HK 09109821A HK 1131340 A1 HK1131340 A1 HK 1131340A1
Authority
HK
Hong Kong
Prior art keywords
muscle performance
ketoglutarate
alpha
compositions
modulating muscle
Prior art date
Application number
HK09109821.7A
Other languages
English (en)
Inventor
Stefan Pierzynowski
Original Assignee
Sgp & Sons Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sgp & Sons Ab filed Critical Sgp & Sons Ab
Publication of HK1131340A1 publication Critical patent/HK1131340A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
HK09109821.7A 2006-04-21 2009-10-22 Compositions comprising alpha-ketoglutarate and their use for modulating muscle performance HK1131340A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL379512A PL379512A1 (pl) 2006-04-21 2006-04-21 Nowe metody i ich zastosowanie
PCT/EP2007/053882 WO2007122190A1 (en) 2006-04-21 2007-04-20 Compositions comprising alpha-ketoglutarate and their use for modulating muscle performance

Publications (1)

Publication Number Publication Date
HK1131340A1 true HK1131340A1 (en) 2010-01-22

Family

ID=38359362

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09109821.7A HK1131340A1 (en) 2006-04-21 2009-10-22 Compositions comprising alpha-ketoglutarate and their use for modulating muscle performance

Country Status (10)

Country Link
US (1) US20090069429A1 (xx)
EP (1) EP2020999B1 (xx)
JP (1) JP2009534360A (xx)
CN (1) CN101426490B (xx)
AT (1) ATE522210T1 (xx)
DK (1) DK2020999T3 (xx)
ES (1) ES2372207T3 (xx)
HK (1) HK1131340A1 (xx)
PL (2) PL379512A1 (xx)
WO (1) WO2007122190A1 (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013026706A2 (pt) * 2011-04-18 2016-12-27 Nestec Sa composições nutricionais compreendendo ácido alfa-hidroxi-isocaproico
ITBO20120226A1 (it) * 2012-04-24 2013-10-25 Alfa Wassermann Spa Composizioni comprendenti ornitina alfa-chetoglutarato, processi per il loro ottenimento e il loro uso.
WO2016083399A1 (en) * 2014-11-24 2016-06-02 Forschungsgesellschaft Für Arbeitsphysiologie Und Arbeitsschutz E. V. Alpha-ketoglutarate in combination with glutamate dehydrogenase for treating hyperammonemia
CN106963749A (zh) * 2017-03-23 2017-07-21 华南农业大学 α‑酮戊二酸（盐）在抗疲劳和提高肌肉运动力量方面的应用
JP2022502489A (ja) 2018-09-25 2022-01-11 ポンス デ レオン ヘルス デジグネイテッド アクティビティ カンパニー αケトグルタル酸カルシウムを製造するためのプロセス
EP3980000A4 (en) * 2019-06-10 2023-06-21 Buck Institute for Research on Aging METHODS AND COMPOSITIONS FOR MODIFYING A SECRETORY PHENOTYPE ASSOCIATED WITH SENESCENCE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8704217D0 (sv) * 1987-10-29 1987-10-29 Vinnars Erik Ab Aminosyrakomposition for parenteral neringstillforsel
SE9303691D0 (sv) * 1993-11-09 1993-11-09 Gramineer Ab New beverage
SE9402027D0 (sv) * 1994-06-10 1994-06-10 Pharmacia Ab Energy substrates
ITRM20010445A1 (it) * 2001-07-25 2003-01-27 Sigma Tau Healthscience Spa Alfa-chetoglutarati di principi attivi e composizioni che li contengono.
EP1638546A1 (en) * 2003-07-01 2006-03-29 Essentys AB Use of alpha-ketoglutaric acid for the treatment of malnutrition or high plasma glucose condition

Also Published As

Publication number Publication date
DK2020999T3 (da) 2011-11-21
JP2009534360A (ja) 2009-09-24
PL2020999T3 (pl) 2012-01-31
ES2372207T3 (es) 2012-01-17
ATE522210T1 (de) 2011-09-15
EP2020999A1 (en) 2009-02-11
PL379512A1 (pl) 2007-10-29
CN101426490A (zh) 2009-05-06
CN101426490B (zh) 2011-01-12
WO2007122190A1 (en) 2007-11-01
EP2020999B1 (en) 2011-08-31
US20090069429A1 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
MX2009006195A (es) Compuestos basados en 4-fenil-6-(2,2,2-trifluoro-1-feniletoxi)piri midina y metodos de su uso.
PH12013500913A1 (en) Substituted-quinoxaline-type-piperidine compounds and the uses thereof
WO2007092622A3 (en) Compositions and methods for treating bone
MX2010001460A (es) Composiciones y metodos para tratamiento de semillas.
ZA200703002B (en) Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
MY153948A (en) Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
WO2007095050A3 (en) N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
IN2012DN00624A (xx)
PT1984357E (pt) Compostos de 2,4-pirimidinadiamina para tratamento ou prevenção de doenças autoimunes
MY152282A (en) Compositions and methods for use antibodies against sclerostin
MX2009000657A (es) Composiciones y metodos para el tratamiento de mucositis.
EA200970933A1 (ru) Способы лечения или профилактики рвоты с помощью агентов, усиливающих секрецию гормона роста
HK1131340A1 (en) Compositions comprising alpha-ketoglutarate and their use for modulating muscle performance
MX2009013353A (es) Compuestos activadores de telomerasa y metodos para su uso.
EA201200428A1 (ru) Композиция и способ для лечения ожирения
MX2009003301A (es) Novedoso inmunogeno neutralizante (nimiv) de rhinovirus y su uso para aplicaciones de vacunas.
SG169346A1 (en) Use of yeast flakes for treating and/or preventing hyperinsulinemia
UA101961C2 (xx) Кристалічна форма 1 2-((r)-2-метилпіролідин-2-іл)-1h-бензімідазол-4-карбоксаміду[кристаллическая форма 1 2-((r)-2-метилпирролидин-2-ил)-1h-бензимидазол-4-карбоксамида
WO2008028003A3 (en) Denture care composition
ATE538799T1 (de) Zusammensetzungen zur behandlung von haarverlust
MX2012003729A (es) Composicion para tratar el mal olor oral.
MX2010003771A (es) Forma cristalina 2 - de 2 ((r)-2-metilpirrolidin-2-il)-1h-benzimid azol-4-carboxamida.
MX2009004633A (es) Composicion solida para tratamiento de agua.
EA200802262A1 (ru) Назальные и буккальные композиции для борьбы с храпом
MX2009010164A (es) Metodo para tratar dolor mediado por el receptor cb2.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150420